KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $2.5 million.

  • Biogen's Exchange Rate Effect rose 10336.02% to $2.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $101.9 million, marking a year-over-year increase of 25051.7%. This contributed to the annual value of $101.9 million for FY2025, which is 25051.7% up from last year.
  • Biogen's Exchange Rate Effect amounted to $2.5 million in Q4 2025, which was up 10336.02% from -$3.2 million recorded in Q3 2025.
  • Biogen's 5-year Exchange Rate Effect high stood at $68.3 million for Q2 2025, and its period low was -$74.4 million during Q4 2024.
  • Moreover, its 5-year median value for Exchange Rate Effect was -$6.8 million (2022), whereas its average is -$2.3 million.
  • Per our database at Business Quant, Biogen's Exchange Rate Effect tumbled by 52500.0% in 2022 and then surged by 64206.35% in 2025.
  • Biogen's Exchange Rate Effect (Quarter) stood at -$15.8 million in 2021, then surged by 525.32% to $67.2 million in 2022, then decreased by 28.72% to $47.9 million in 2023, then plummeted by 255.32% to -$74.4 million in 2024, then skyrocketed by 103.36% to $2.5 million in 2025.
  • Its Exchange Rate Effect was $2.5 million in Q4 2025, compared to -$3.2 million in Q3 2025 and $68.3 million in Q2 2025.